Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Tiede

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
European Journal of Haematology|February 24, 2023
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trialFrank W G Leebeek, Flora Peyvandi, Andreas Tiede, et al.
Xenotransplantation|January 17, 2016
Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulationDennis Rataj, Sonja Werwitzke, Birgitt Haarmeijer, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
Blood Advances|August 10, 2022
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 studyOlga Oleshko, Sonja Werwitzke, Annika Klingberg, et al.
Blood|February 26, 2016
Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 studyAndreas Tiede, Christoph J Hofbauer, Sonja Werwitzke, et al.
Thrombosis Research|June 21, 2024
Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor-associated major bleedsRaza Alikhan, May Nour, Masahiro Yasaka, et al.
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Cell Death Discovery|October 25, 2023
The monosialoganglioside GM1a protects against complement attackHenri Wedekind, Julia Beimdiek, Charlotte Rossdam, et al.
Xenotransplantation|July 29, 2015
Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneysWolf Ramackers, Johannes Klose, Andreas Tiede, et al.
Critical Care (London, England)|January 5, 2021
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failureBenjamin Seeliger, Michael Döbler, Robert Friedrich, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
European Journal of Haematology|February 24, 2023
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trialFrank W G Leebeek, Flora Peyvandi, Andreas Tiede, et al.
Xenotransplantation|January 17, 2016
Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulationDennis Rataj, Sonja Werwitzke, Birgitt Haarmeijer, et al.
Hamostaseologie|December 4, 2023
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working GroupChristian Pfrepper, Robert Klamroth, Johannes Oldenburg, et al.
Blood Advances|August 10, 2022
Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 studyOlga Oleshko, Sonja Werwitzke, Annika Klingberg, et al.
Blood|February 26, 2016
Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 studyAndreas Tiede, Christoph J Hofbauer, Sonja Werwitzke, et al.
Thrombosis Research|June 21, 2024
Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor-associated major bleedsRaza Alikhan, May Nour, Masahiro Yasaka, et al.
Blood|December 18, 2012
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsShawn F J Whelan, Christoph J Hofbauer, Frank M Horling, et al.
Cell Death Discovery|October 25, 2023
The monosialoganglioside GM1a protects against complement attackHenri Wedekind, Julia Beimdiek, Charlotte Rossdam, et al.
Xenotransplantation|July 29, 2015
Effect of TNF-alpha blockade on coagulopathy and endothelial cell activation in xenoperfused porcine kidneysWolf Ramackers, Johannes Klose, Andreas Tiede, et al.
Critical Care (London, England)|January 5, 2021
Comparison of anticoagulation strategies for veno-venous ECMO support in acute respiratory failureBenjamin Seeliger, Michael Döbler, Robert Friedrich, et al.
Pageof 13